D. M. Canafax

659 total citations
45 papers, 538 citations indexed

About

D. M. Canafax is a scholar working on Transplantation, Surgery and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, D. M. Canafax has authored 45 papers receiving a total of 538 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Transplantation, 13 papers in Surgery and 9 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in D. M. Canafax's work include Renal Transplantation Outcomes and Treatments (27 papers), Pharmacological Effects and Toxicity Studies (9 papers) and Organ Transplantation Techniques and Outcomes (8 papers). D. M. Canafax is often cited by papers focused on Renal Transplantation Outcomes and Treatments (27 papers), Pharmacological Effects and Toxicity Studies (9 papers) and Organ Transplantation Techniques and Outcomes (8 papers). D. M. Canafax collaborates with scholars based in United States. D. M. Canafax's co-authors include Arthur J. Matas, John S. Najarian, Kristen J. Gillingham, David L. Dunn, Philip M. Becker, Clete A. Kushida, Aaron Ellenbogen, Ronald W. Barrett, G. Scott Giebink and Kathleen D. Lake and has published in prestigious journals such as Neurology, Diabetes Care and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

D. M. Canafax

45 papers receiving 513 citations

Peers

D. M. Canafax
Allison Wehr United States
Dana Jorgensen United States
Edward E. Etheredge United States
Waldemar F. Carlo United States
Osemwegie Emovon United States
Elliot Grodstein United States
Allison Wehr United States
D. M. Canafax
Citations per year, relative to D. M. Canafax D. M. Canafax (= 1×) peers Allison Wehr

Countries citing papers authored by D. M. Canafax

Since Specialization
Citations

This map shows the geographic impact of D. M. Canafax's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. M. Canafax with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. M. Canafax more than expected).

Fields of papers citing papers by D. M. Canafax

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. M. Canafax. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. M. Canafax. The network helps show where D. M. Canafax may publish in the future.

Co-authorship network of co-authors of D. M. Canafax

This figure shows the co-authorship network connecting the top 25 collaborators of D. M. Canafax. A scholar is included among the top collaborators of D. M. Canafax based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. M. Canafax. D. M. Canafax is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
Singla, Neil, D. M. Canafax, A H Kang, et al.. (2013). TD-1211 demonstrates tolerability and clinical activity following multiple treatment administration strategies in patients with opioid-induced constipation (OIC). Journal of Pain. 14(4). S70–S70. 1 indexed citations
3.
Fisher, Robert A., et al.. (1999). Pharmacokinetic comparison of two cyclosporine A formulations, SangCya (Sang-35) and Neoral, in stable adult liver transplant recipients. Transplantation Proceedings. 31(1-2). 394–395. 6 indexed citations
4.
First, M. Roy, P Weiskittel, Malay B. Shah, et al.. (1998). Conversion of stable renal transplant recipients from sandimmune to sang-35, a novel cyclosporine formulation, using a dose-normalized equivalence method. Transplantation Proceedings. 30(5). 1701–1705. 4 indexed citations
5.
First, M. Roy, P Weiskittel, Malay B. Shah, et al.. (1998). Conversion of stable renal transplant recipients from sandimmune to sang-35, a neoral-equivalent cyclosporine formulation, using a dose-adjusted method. Transplantation Proceedings. 30(8). 3955–3957. 1 indexed citations
6.
Johnson, Eileen, D. M. Canafax, Kristen J. Gillingham, et al.. (1997). Effect of early cyclosporine levels on kidney allograft rejection. Clinical Transplantation. 11(6). 552–557. 31 indexed citations
7.
Johnson, Eileen, Janice L. Zimmerman, Jenny Chambers, et al.. (1996). A randomized, double-blind, placebo-controlled study of the safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients.. PubMed. 28(2). 987–987. 26 indexed citations
8.
Johnson, Eileen, et al.. (1996). Do early cyclosporine levels affect the incidence of acute rejection in renal transplant recipients?. PubMed. 28(2). 879–879. 1 indexed citations
9.
Granger, Darla K., et al.. (1994). Cyclosporine levels impact early rejection episodes.. PubMed. 26(5). 2513–2513. 1 indexed citations
10.
Frey, Daniel, Arthur J. Matas, Kristen J. Gillingham, et al.. (1992). SEQUENTIAL THERAPY—A PROSPECTIVE RANDOMIZED TRIAL OF MALG VERSUS OKT3 FOR PROPHYLACTIC IMMUNOSUPPRESSION IN CADAVER RENAL ALLOGRAFT RECIPIENTS. Transplantation. 54(1). 50–55. 55 indexed citations
11.
Gruber, Saskia, Gary L. C. Chan, D. M. Canafax, & A. J. Matas. (1991). Immunosuppression in renal transplantation I. Cyclosporine and azathioprine. Clinical Transplantation. 5(2pt1). 65–85. 14 indexed citations
12.
Wrenshall, Lucile E., A. J. Matas, D. M. Canafax, et al.. (1990). AN INCREASED INCIDENCE OF LATE ACUTE REJECTION EPISODES IN CADAVER RENAL ALLOGRAFT RECIPIENTS GIVEN AZATHIOPRINE, CYCLOSPORINE, AND PREDNISONE. Transplantation. 50(2). 233–236. 30 indexed citations
13.
Canafax, D. M., Dullei Min, Arthur J. Matas, et al.. (1990). Effects of initial cyclosporine dose and timing on long‐term creatinine levels in cadaver renal transplantation. Clinical Transplantation. 4(5pt2). 321–328. 8 indexed citations
14.
Gruber, S. A., Robert J. Cipolle, D. M. Canafax, et al.. (1990). Pharmacodynamics of local heparin infusion in a canine renal allograft model.. Journal of Pharmacology and Experimental Therapeutics. 252(2). 733–738. 3 indexed citations
15.
Chan, Gary L. C., Gary R. Erdmann, S. A. Gruber, et al.. (1989). Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine. European Journal of Clinical Pharmacology. 36(3). 265–271. 17 indexed citations
16.
Gruber, S. A., Barbara A. Burke, D. M. Canafax, et al.. (1989). Feasibility of vascular catheter placement for intrarenal infusion in a canine autotransplant model.. PubMed. 21(1 Pt 1). 1125–6. 4 indexed citations
17.
Burke, George W., Richard L. Simmons, D. M. Canafax, et al.. (1988). Initial experience with OKT3 for prophylaxis and treatment of rejection in kidney, liver, and pancreas allografts. Transplantation Proceedings. 20. 252–253. 1 indexed citations
18.
Erdmann, Gary R., D. M. Canafax, & G. Scott Giebink. (1988). High-performance liquid chromatographic analysis of trimethoprim and sulfamethoxazole in microliter volumes of chinchilla middle ear effusion and serum. Journal of Chromatography B Biomedical Sciences and Applications. 433. 187–195. 22 indexed citations
19.
Ford, Henri R., David S. Fryd, D. M. Canafax, et al.. (1988). Adjunctive azathioprine and antilymphocyte serum immunosuppression with cyclosporine.. PubMed. 20(3 Suppl 3). 8–12. 2 indexed citations
20.
McHugh, Lois, D. M. Canafax, D. E. R. Sutherland, et al.. (1987). Cyclosporine, combination immunosuppression, and posttransplant diabetes mellitus.. PubMed. 19(1 Pt 2). 1811–3. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026